UK’s NICE backs Bayer’s Xarelto for reducing risk of secondary events in ACS

23 January 2015

The National Institute for Health and Care Excellence (NICE), the health costs watchdog for England, today issued its final appraisal determination (FAD) for German pharma major Bayer’s (BAYN: DE) already blockbuster oral Factor Xa inhibitor Xarelto (rivaroxaban) in a new indication.

NICE is recommending Xarelto 2.5mg twice daily as an effective treatment option for preventing secondary events – such as death, heart attack or stroke – following acute coronary syndrome (ACS) in patients with elevated cardiac biomarkers, without prior stroke or transient ischemic attack (TIA).

The FAD is the final phase in a multi-step review process by NICE and recognizes the improved patient outcomes using Xarelto as a treatment option on top of dual antiplatelet therapy; publication of guidance is expected to follow in first-quarter 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK